Diet and Fasting for Long COVID

Long COVID Clinical Trial

Official title:

The Effect of a No-added Sugar Diet, Time-restricted Eating and Periodic Water Fasting on Long COVID Symptoms

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06214455
• Other study ID #: 2022-06-PNWU
• Status: Active, not recruiting
• Phase: N/A
• Start date: November 4, 2022
• Est. completion date: November 22, 2024

Study information

• Verified date: June 2024
• Source: Pacific Northwest University of Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This cross-over study will assess a no added sugar diet, a restricted daily eating window, and one or two full day water fasts to determine if there is an effect on self-reported symptoms of Long Covid (PASC).

Description:

This remote study will use a cross-over design to test a diet change plus a 10-12 hour eating window (Treatment A) compared to a diet change, an 8-hour eating window, and one 36 or 60 hour fast per week (Treatment B). Both potential Treatment A and potential Treatment B are 4 weeks in duration. To be eligible, subjects must have a minimum of five common long COVID-19 symptoms. The fasting will limit food intake but not water intake. There will be a two-week run-in with weekly surveys of patient-reported symptoms and severity. The subjects will be randomly assigned to Group AB or to Group BA. Since the water fasts are at the beginning of the week (with symptoms surveyed at the end of the week) there is a 5-6 day washout and then a cross-over to the other treatment for Group BA. A Likert 0-4 scale is used to track the severity of 28 of the most common patient-reported symptoms each week. An additional 30 symptoms are also tracked. Subjects are asked to follow a no-added sugar diet for the entire 10 weeks of the study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 180
• Est. completion date: November 22, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 69 Years

Eligibility

Inclusion Criteria

• Adult (18-69 years old)

• Five or more common Long Covid symptoms

• Free from fever > 100F and known bacterial and parasitic infections

• Must indicate willingness to limit certain supplements and report all medications.

• Must indicate willingness to make significant dietary changes - and limit daily eating to an 8 or 10 hour window.

• Must indicate willingness to attempt 36 hr or 60 hr water fasts each week for 4 weeks.

• Have a valid email address and phone number

• Reside in the United States

• Be able to read and to communicate in English

• Must indicate willingness to avoid "extra" supplements such as Fish Yes Oil, Cod liver Oil, Krill Oil, MCT oil, Coconut Oil, Tumeric/Curcumin, Berberine, Quercetin (> 500 mg), Red Yeast Rice, French Marine Bark extract, Red Sage, Ginko biloba, Oregano Oil, Peppermint Oil, Black seed oil, Cinnamon bark extract, Elderberry, Stinging Nettle, Milk Thistle, Monolaurin, Vendicinals 9, Tollovid, QuadraMune and all Probiotics.

• Must indicate willingness to avoid certain nutraceuticals such as Zinc (more than 25 mg), Arginine, Glutamine, Palmitoylethanolamide (PEA), Alpha Lipoic Acid, L Carnitine and Taurine during the study period.

• Must indicate willingness to avoid longevity supplements such as NAD+, Niacin, NMN, Nicotinamide Riboside, Spermidine and Fisetin during the study period.

• Must indicate willingness to halt Olive oil consumption greater than 1 tsp daily during the study period.

Exclusion Criteria:

• Likely COVID-19 or SARS-CoV-2 infection < 45 days before enrollment

• Body Mass Index (BMI) must be 20 or greater

• Past history of an eating disorder.

• Previously fasted more than 18 hours with Long COVID

• Currently doing intermittent fasting

• Pregnant or breast-feeding

• Severe pulmonary disease requiring supplemental oxygen

• Partial loss of vision due to macular degeneration

• Any recent (90 days) history of malignancies, fractures, surgery, radiation, chemo, anesthesia, or traumas

• Diagnosed with Type I or Type II Diabetes

• Previous Autoimmune condition

• Heart condition (Coronary artery disease, Heart valve disease, Heart No failure, Stroke)

• Pre-pandemic Arrythmia

• Liver disease

• Previous Chronic Health Conditions that did not fully resolve (Includes ME/CFS, Lyme Disease, and Fibromyalgia)

• Prescription anticoagulation medication that cannot be halted during the study period. Brilinta (ticagrelor), Plavix (clopidogrel), Coumadin, Warfarin etc.

• High Cholesterol medications that cannot be halted or reduced during the study period (Fenofibrate, Statins > 10 mg)

• Anti-inflammatories or immunosuppressants such as Steroids, Low dose Naltrexone (LDN), Maraviroc, Remicade/Infliximab or Colchicine that cannot be halted during the study period

• Metformin, Ivermectin, or peptides such as BCP-157 that cannot be halted during the study period

Related Conditions & MeSH terms

• COVID-19
• Long COVID

Intervention

Other:
• Low sugar diet and 10-12 hour eating window
Low sugar diet and 10-12 hour eating window for four weeks
• Low sugar diet, 8 hour eating window and fasting
Low sugar diet, 8 hour eating window and a 36-60 hour fast once per week for four weeks.

Locations

Country	Name	City	State
United States	Remote trial - anyone residing in the United States	Boulder	Colorado
United States	Pacific Northwest University	Yakima	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Pacific Northwest University of Health Sciences

Country where clinical trial is conducted

United States, 

References & Publications (10)

Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, Tan B, Tay ZEA, Wan WY, Chen EX, Nerurkar SN, Loong S, Cheow PC, Chan CY, Koh YX, Tan TT, Kalimuddin S, Tai WMD, Ng JL, Low JG, Yeong J, Lim KH. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. 2022 Jan;71(1):226-229. doi: 10.1136/gutjnl-2021-324280. Epub 2021 Jun 2. No abstract available. Erratum In: Gut. 2022 Aug;71(8):e9. — View Citation

Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021 Aug;38:101019. doi: 10.1016/j.eclinm.2021.101019. Epub 2021 Jul 15. — View Citation

Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004 Mar 5;303(5663):1529-31. doi: 10.1126/science.1093616. Epub 2004 Feb 19. — View Citation

Girdhar K, Powis A, Raisingani A, Chrudinova M, Huang R, Tran T, Sevgi K, Dogus Dogru Y, Altindis E. Viruses and Metabolism: The Effects of Viral Infections and Viral Insulins on Host Metabolism. Annu Rev Virol. 2021 Sep 29;8(1):373-391. doi: 10.1146/annurev-virology-091919-102416. — View Citation

Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021 Jun 17;10(6):763. doi: 10.3390/pathogens10060763. — View Citation

Hannan MA, Rahman MA, Rahman MS, Sohag AAM, Dash R, Hossain KS, Farjana M, Uddin MJ. Intermittent fasting, a possible priming tool for host defense against SARS-CoV-2 infection: Crosstalk among calorie restriction, autophagy and immune response. Immunol Lett. 2020 Oct;226:38-45. doi: 10.1016/j.imlet.2020.07.001. Epub 2020 Jul 10. — View Citation

Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004 Mar 5;303(5663):1526-9. doi: 10.1126/science.1093620. Epub 2004 Feb 19. — View Citation

Kim H, Rebholz CM, Hegde S, LaFiura C, Raghavan M, Lloyd JF, Cheng S, Seidelmann SB. Plant-based diets, pescatarian diets and COVID-19 severity: a population-based case-control study in six countries. BMJ Nutr Prev Health. 2021 Jun 7;4(1):257-266. doi: 10.1136/bmjnph-2021-000272. eCollection 2021. — View Citation

Koepke L, Hirschenberger M, Hayn M, Kirchhoff F, Sparrer KM. Manipulation of autophagy by SARS-CoV-2 proteins. Autophagy. 2021 Sep;17(9):2659-2661. doi: 10.1080/15548627.2021.1953847. Epub 2021 Jul 19. — View Citation

Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, Winkler CW, Sun J, Dickey JM, Ylaya K, Ko SH, Platt AP, Burbelo PD, Quezado M, Pittaluga S, Purcell M, Munster VJ, Belinky F, Ramos-Benitez MJ, Boritz EA, Lach IA, Herr DL, Rabin J, Saharia KK, Madathil RJ, Tabatabai A, Soherwardi S, McCurdy MT; NIH COVID-19 Autopsy Consortium; Peterson KE, Cohen JI, de Wit E, Vannella KM, Hewitt SM, Kleiner DE, Chertow DS. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022 Dec;612(7941):758-763. doi: 10.1038/s41586-022-05542-y. Epub 2022 Dec 14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Long COVID Symptom Scores during Treatment A vs Treatment B	Long COVID Symptom Severity Scores are calculated from weekly surveys using a (0-4) severity scale for each of 28 patient-reported symptoms commonly found in Long COVID. The symptom severity values are summed for each participant. That severity subtotal is then added to the number of 30 additional symptoms that were reported.	4 weeks for each treatment
Primary	Change in number of Long COVID symptoms during Treatment A vs Treatment B	The total number of patient-reported symptoms is calculated from the weekly symptom surveys. The value at the end of the 4 week treatment period is subtracted from the value at the beginning of the 4 week treatment period.	4 weeks for each treatment (delta from week 6 to week 2 or from week 10 to week 6)
Secondary	Change in Long COVID Symptom Scores during the 10 week trial	Long COVID Symptom Severity Scores are calculated from weekly surveys using a (0-4) severity scale for each of 28 patient-reported symptoms commonly found in Long COVID. The symptom severity values are summed for each participant. That severity subtotal is then added to the number of 30 additional symptoms that were reported.	10 weeks (delta from week 10 to week 0)
Secondary	Change in number of Long COVID symptoms during the 10 week trial	The total number of patient-reported symptoms is calculated from the weekly symptom surveys. The value at the end of the 4 week treatment period is subtracted from the value at the beginning of the 4 week treatment period.	10 weeks (delta from week 10 to week 0)
Secondary	Number of participants With Serious and Concerning Adverse Events	All adverse events will be medically reviewed and judged to be; not related, possibly related, or definitely related to the treatment intervention.	2 week baseline, 4 weeks for Treatment A, 4 weeks for Treatment B, 10 weeks of the study